SCHEMBL1198599

SCHEMBL1198599

CCOC(=O)c1cnn(Cc2nc(-c3cc(F)cc(C(F)(F)F)c3)sc2C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.43
MAPT P10636 3/20 0.43
KMT2A Q03164 3/20 0.43
GRM2 Q14416 1/20 0.42
KDM4E B2RXH2 4/20 0.41
HSP90AA1 P07900 1/20 0.41
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41
RARA P10276 2/20 0.38
RARB P10826 2/20 0.38
RARG P13631 2/20 0.38
ALDH1A1 P00352 4/20 0.37
HPGD P15428 3/20 0.37
CYP1A2 P05177 2/20 0.37
CYP2C9 P11712 2/20 0.37
CYP2C19 P33261 2/20 0.37
TRPM8 Q7Z2W7 3/20 0.37
L3MBTL1 Q9Y468 3/20 0.36
GAA P10253 2/20 0.36
GRM5 P41594 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1198829 0.91 MEN1 (0.45) MEN1MAPTKMT2AGRM2KDM4E
SCHEMBL1198939 0.91 MAPT (0.43) MEN1MAPTKMT2AGRM2KDM4E
SCHEMBL1199152 0.90 MAPT (0.44) MEN1MAPTKMT2AGRM2KDM4E
SCHEMBL1198731 0.89 RXRA (0.37) MEN1KMT2AALDH1A1L3MBTL1PPARG
SCHEMBL12876099 0.89 GRM2 (0.45) MAPTGRM2KDM4ERARARARB
SCHEMBL12890247 0.89 MAPT (0.41) MEN1MAPTKMT2AGRM2KDM4E
SCHEMBL1199200 0.88 MAPT (0.57) MEN1MAPTKMT2AGRM2KDM4E
Hydrochloric Acid SCHEMBL1198718 0.88 MAPT (0.41) MEN1MAPTKMT2AGRM2KDM4E
SCHEMBL1197781 0.85 MAPT (0.42) MEN1MAPTKMT2AGRM2KDM4E
SCHEMBL1197779 0.85 MAPT (0.42) MEN1MAPTKMT2AGRM2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A MEN1 2661/4885MAPT 4667/4885KMT2A 3197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.